• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pharma

BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial

byUsamah BhaiduandFlaviu Trifoi
September 3, 2024
in Pharma
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter
  1. Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma compared to therapy with cemiplimab alone.
  2. BNT111 was well tolerated by participants.

The Latest

In a collaboration between BioNTech and Regeneron, researchers performed an open-label, randomized phase 2 clinical trial evaluating the efficacy of BioNTech’s BNT111 and Regeneron’s anti-PD-1 inhibitor cemiplimab in the treatment of inoperable or advanced-stage anti-PD-1 inhibitor-resistant melanoma. The study showed that patients taking the combination BNT111/cemiplimab experienced a significantly improved overall response rate and the drug was well tolerated. Next, researchers hope to continue working on the secondary endpoints in this trial and present their full results shortly.

Physician’s Perspective

Melanoma is a type of skin cancer and is the most common cause of skin cancer-related deaths. Repeated exposure to ultraviolet radiation (from the sun or tanning beds) tends to be the most common cause of melanoma. The immune system attempts to fight cancer cells by expressing a protein on their surface called PD-1. PD-1 on T cells binds to PD ligand (PDL) on normal host cells to prevent their degradation. Melanoma cells exploit this checkpoint by expressing their own PDLs which deceive T cells into perceiving the cancerous cells as normal cells. In advanced cancers, one mode of treatment uses anti-PD-1 antibodies to prevent melanoma from using this exploitation. However, some advanced forms of melanoma are resistant to anti-PD-1 antibody treatment. BioNTech’s BNT111 hopes to improve the treatment of anti-PD1 inhibitor-resistant melanoma by targeting this mechanism.

Molecular Target of Therapy

Most melanoma cells express specific antigens on their surface which can be recognized by the immune system as foreign and marked for destruction. BNT111 is an mRNA-based treatment delivered to melanoma cells causing the production of such specific antigens on their surface. This makes cancer cells recognizable to the immune system. Ultimately, BNT111 boosts the immune response towards melanoma and increases the efficacy of cemiplimab when the two are used in combination.

RELATED REPORTS

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

Company History

BioNTech is a biotechnology company based in Germany that specializes in next-generation immunotherapy. The company became well known recently for its collaborative effort with Pfizer in the development of the mRNA-based covid-19 vaccine. Presently, the company has over 30 candidates in various stages of clinical research. These are mRNA-based candidates for the treatment of cancers ranging from lung to colorectal to pancreatic, as well as other diseases like tuberculosis and malaria.

 

Further reading: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-positive-topline-phase-2-results-mrna

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: biontechbnt111cemiplimabmelanoma
Previous Post

Individualized acupuncture not associated with significant improvements in chronic neck pain

Next Post

#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

RelatedReports

Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025
“No Evidence of Disease Activity” may be useful goal in multiple sclerosis
Chronic Disease

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

February 24, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
Medicare beneficiaries have a lower rate of delayed melanoma surgeries
Chronic Disease

Adjuvant dabrafenib and trametinib improve survival in stage III melanoma

November 25, 2024
Next Post
#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

Intravenous amino acids decrease acute kidney injury following cardiac surgery

Oseltamivir and peramivir may reduce length-of-hospital-stay in patients with severe influenza

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF
  • #VisualAbstract: Efruxifermin Did Not Reduce Liver Fibrosis in Compensated Liver Cirrhosis Caused by MASH
  • Diabetic polyneuropathy observed to have dynamic changes overtime
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.